Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hematological Toxicities with PARP Inhibitors in Prostate Cancer: A Systematic Review and Meta-Analysis of Phase II/III Randomized Controlled Trials.

Cancers·2023
Same author

Prognostic Features of Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy Based on Multiparametric MRI and Immunohistochemistry Analysis of MRI-guided Biopsy Specimens.

Radiology·2021
See all related articles

Related Experiment Video

Updated: Aug 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K

Emerging Developments in ETS-Positive Prostate Cancer Therapy.

Gartrell C Bowling1,2, Mitchell G Rands1, Albert Dobi2,3

  • 1School of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland.

Molecular Cancer Therapeutics
|December 13, 2022
PubMed
Summary

Targeting E-26 transformation-specific (ETS) transcription factors offers a promising strategy for advanced prostate cancer. Inhibiting ETS activity, particularly ETS-related gene (ERG), shows potential in reducing tumor growth and improving outcomes.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Related Experiment Videos

Last Updated: Aug 17, 2025

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.3K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Prostate cancer, especially in advanced stages, presents a significant global health challenge with poor survival rates.
  • Current treatments like androgen receptor-axis inhibitors often lead to castration-resistant prostate cancer, necessitating novel therapeutic strategies.
  • ETS gene rearrangements are key drivers in a substantial number of prostate cancer cases, influencing initiation and progression.

Approach:

  • This review explores molecular-targeted therapies aimed at suppressing E-26 transformation-specific (ETS) transcription factor activity.
  • Various drug modalities, including small molecules, peptidomimetics, and nucleic acids, are discussed for their potential to inhibit ETS.
  • The focus is on targeting ETS-related gene (ERG) as a critical oncogene in prostate cancer.

Key Points:

  • Inhibition of ETS activity has demonstrated a reduction in tumorigenesis, establishing it as a viable clinical therapeutic target.
  • Several compounds exhibit ERG antagonist activity, showing promise in preclinical or early clinical settings.
  • Understanding the precise molecular mechanisms and off-target effects on non-tumor tissues is crucial for further development.

Conclusions:

  • Targeted inhibition of ETS transcription factors represents a rational approach to combatting castration-resistant prostate cancer.
  • Developing effective ETS inhibitors could overcome limitations of current therapies and improve patient prognosis.
  • Further research is essential to refine these targeted therapies and ensure their safety and efficacy.